Early Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEEL-224 in Patients With Advanced Solid Tumors, Including Pancreatic Cancer
The purpose of this phase I study is to evaluate the safety and feasibility of PEEL-224 in patients with advanced solid tumors, including pancreatic cancer.
Study ID: PEEL-224-001
Trial Phase: Phase I
Trial Sponsor: Peel Therapeutics Inc
Therapies Used in This Trial: PEEL-224